Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA grants orphan drug status to Syros’ myelodysplastic syndrome therapy

Pharmaceutical-TechnologyFebruary 07, 2022

Tag: Orphan Drug , oral therapy , tamibarotene

PharmaSources Customer Service